



Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024
Grand Walkerhill Seoul, Korea

"Pioneering the future of digestive diseases"



SIDDS 2024

Name	Sang Bong Ahn
Affiliation	Nowon Eulji Medical Center
Country	Korea
Major Field	NAFLD, HBV

Educational Background

Hanyang University, College of Medicine, Bachelor's degree (2003)
 Hanyang University, College of Medicine, Master's degree (2007)
 Hanyang University, College of Medicine, Doctor's degree (2016)

Professional Experience

Hanyang University Guri Hospital, Fellowship (2008-2010)
 Nowon Eulji Medical Center, Assistant professor (2010-2016)
 Nowon Eulji Medical Center, Associate professor (2016-2020)
 Nowon Eulji Medical Center, Professor (2020-)
 University of Queensland, AU, Visting Scholar (2019-2020)

Main Scientific Publications

Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area. *Cancers*. 2023 Dec

Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis. *Nutrients*. 2023 Dec

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments. *Clin Mol Hepatol*. 2023 Feb

Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study. *Aliment Pharmacol Ther*. 2024 Jan

Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. *Clin Gastroenterol Hepatol*. 2023 Sep

Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. *Dig Liver Dis*. 2023 Jan

Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study. *Am J Gastroenterol*. 2023 Mar 7

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. *J Pers Med*. 2022 Nov 26

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A



Systematic Review and Meta-Analysis. *J Pers Med.* 2022 Sep

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. *Hepatol Int.* 2022 Dec

Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly. *Clin Mol Hepatol.* 2023 Jan;29(1):120-134.

Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *Nutrients.* 2022 Jul 24;14(15):3039

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults. *Clin Mol Hepatol.* 2022 Oct;28(4):814-826

A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population. *Sci Rep.* 2023 Sep

Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. *Korean J Intern Med.* 2022 Jul;37(4):757-767.

Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥ 65 years old): A systematic review and meta-analysis. *J Viral Hepat.* 2022 Jul;29(7):496-517.

Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Gut Liver.* 2022 Nov 15;16(6):952-963

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. *Hepatol Int.* 2022 Feb;16(1):48-58.

BTT-105 ameliorates hepatic fibrosis in non-alcoholic fatty liver animal model. *FASEB J.* 2021 Nov;35(11):e21979

On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. *Liver Int.* 2022 Jan;42(1):59-68

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. *Clin Gastroenterol Hepatol.* 2022 Jun;20(6):1343-1353